Solid Biosciences Inc. SLDB R2K

Healthcare · Biotechnology · United States

https://www.solidbio.com

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Market & Price

Market Cap

$722.62M

Current Price

$7.34

High / Low (52W)

$8.63 / $3.21

Beta

2.47

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$3.80

Price to Book

1.93

P/S

EV/EBITDA

-1.86

Dividend Yield

Profitability & Returns

ROCE

-90.02%

ROE

-57.37%

ROA

-32.03%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.52

EPS (TTM)

$-1.92

Balance Sheet & Liquidity

Debt/Equity

0.06

Quick Ratio

12.57

Current Ratio

13.10

Debt

$20.67M

Total Assets

$232.54M

Current Assets

$205.46M

Working Capital

$171.98M

Ownership

Promoter Holding

0.82%

Chg in Prom Hold

FII / Inst Holding

101.69%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$362.61M

Total Revenue (TTM)

EBITDA

$-194.84M

Free Cash Flow

$-110.97M

Operating Cash Flow

$-171.67M

Shares Outstanding

98.45M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-33.33%

Profit 5Y

-34.25%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -33.3% CAGR over 5 years.
Earnings shrank at -34.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SLDB Solid Biosciences Inc. R2K	7.34	-	$722.62M	-	-90.02%	-57.37%	-33.33%	-34.25%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40.05M	41.69M	48.06M	49.40M	57.31M
Operating Income	-14.11M	-11.89M	-13.70M	-15.16M	-15.97M	-18.18M	-19.15M	-22.39M	-30.30M	-26.97M	-29.72M	-32.33M	-26.86M	-18.97M	-21.23M	-16.89M	-18.68M	-18.03M	-25.37M	-25.38M	-21.13M	-32.03M	-26.84M	-23.11M	-26.86M	-27.79M	-	-	-40.05M	-41.69M	-48.06M	-49.40M	-57.31M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38.81M	-39.03M	-47.68M	-48.94M	-56.34M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	82.00K	75.00K	68.00K	60.00K	-	-	0
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-39.28M	-39.48M	-45.78M	-49.79M	-56.74M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-12.81M	-11.31M	-13.51M	-14.49M	-15.88M	-17.98M	-19.02M	-21.92M	-29.58M	-26.52M	-29.25M	-	-26.69M	-18.99M	-21.25M	-16.90M	-18.70M	-17.98M	-	-	-	-	-	-	-	-	-	-	-39.28M	-39.48M	-45.78M	-49.79M	-56.74M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.17	-2.40	-3.37	-3.33	-2.71	-1.54	-1.25	-1.05	-0.64	-0.61	-0.79	-	-0.59	-0.42	-0.48	-	-0.52
R&D Expense	8.73M	8.61M	10.62M	-	11.93M	13.59M	14.68M	-	23.27M	21.61M	22.79M	-	19.66M	13.45M	16.05M	14.21M	15.51M	14.43M	19.95M	23.18M	14.01M	24.63M	19.78M	16.70M	18.87M	19.46M	27.33M	-	30.91M	32.41M	38.86M	-	46.14M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	0	0	0	0	0	-	8.09M	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	107.37M	104.31M	129.73M	179.21M
Operating Income	-25.58M	-54.86M	-75.69M	-119.32M	-88.41M	-	-99.27M	-104.31M	-129.73M	-179.21M
EBITDA	-	-	-	-	-	-	-96.87M	-92.99M	-121.90M	-177.57M
Interest Expense	-	-	-	-	-	-	-	440.00K	340.00K	-
Pretax Income	-	-	-	-	-	-	-85.98M	-96.02M	-124.70M	-174.32M
Tax Provision	-	-	-	-	-	-	-	-	-	-
Net Income	-21.54M	-52.12M	-74.80M	-117.22M	-	-	-85.98M	-96.02M	-124.70M	-174.32M
Diluted EPS	-	-	-	-	-25.50	-10.14	-10.10	-4.83	-3.06	-
R&D Expense	20.12M	39.91M	57.97M	94.74M	64.88M	58.74M	78.42M	76.56M	96.43M	140.32M

Compounded Sales Growth

5 Years:	-33.33%
1 Year:	-

Compounded Profit Growth

5 Years:	-34.25%
1 Year:	-

Stock Price Performance

1 Year:	+128.66%
6 Months:	+42.52%
3 Months:	+18.20%
1 Month:	+4.11%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	76.19M	139.60M	103.47M	171.17M	-	260.25M	164.94M	188.66M	232.54M
Current Assets	-	-	-	-	-	-	219.64M	129.73M	157.30M	205.46M
Cash & Equivalents	7.68M	52.08M	86.37M	76.04M	154.74M	-	155.38M	74.02M	80.23M	59.90M
Inventory	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	110.00K	0	-	-	-
Total Liabilities	-	11.27M	14.41M	23.42M	39.08M	-	48.59M	38.46M	51.42M	52.53M
Current Liabilities	-	11.27M	12.48M	18.28M	24.48M	-	22.51M	14.52M	30.26M	33.47M
Long Term Debt	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	28.55M	26.27M	24.18M	21.16M
Total Equity	-	-	125.18M	80.05M	132.09M	-	211.67M	126.48M	137.25M	180.01M
Shares Outstanding	-	-	-	-	-	-	19.56M	20.39M	40.47M	78.97M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-20.12M	-43.22M	-70.20M	-92.71M	-56.60M	-	-97.98M	-94.18M	-100.01M	-156.29M
Investing Cash Flow	-4.05M	10.45M	-26.76M	24.52M	6.60M	-	59.16M	9.69M	-16.09M	-58.45M
Financing Cash Flow	3.42M	77.08M	131.51M	57.88M	128.70M	-	74.83M	3.12M	122.44M	194.45M
Capital Expenditure	-392.00K	-2.28M	-7.78M	-4.39M	-899.00K	-	-3.02M	-1.51M	-654.00K	-1.15M
Free Cash Flow	-20.51M	-45.50M	-77.97M	-97.10M	-57.50M	-	-100.99M	-95.69M	-100.67M	-157.44M
Net Change in Cash	-	-	-	-	-	-	36.01M	-81.37M	6.34M	-20.30M

Ratios (Annual)

Figures in %.

Metric	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-1,226.5%	-	-	-
Net Margin %	-	-	-	-	-	-	-1,062.3%	-	-	-
ROE %	-	-	-59.8%	-146.4%	-	-	-40.6%	-75.9%	-90.9%	-96.8%
ROCE %	-	-84.5%	-59.5%	-140.1%	-60.3%	-	-41.8%	-69.3%	-81.9%	-90.0%

Shareholding Pattern

Insiders

0.82%

Institutions

101.69%

Public Float

102.53%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Perceptive Advisors Llc	12.09%	11.91M	$87.39M
2	Bain Capital Life Sciences Investors, LLC	9.96%	9.81M	$72.00M
3	RA Capital Management, L.P.	9.49%	9.34M	$68.56M
4	Siren, L.L.C.	7.81%	7.69M	$56.45M
5	Vestal Point Capital, LP	5.08%	5.00M	$36.70M
6	Blackrock Inc.	5.04%	4.96M	$36.39M
7	Janus Henderson Group PLC	4.07%	4.01M	$29.44M
8	FMR, LLC	3.66%	3.61M	$26.47M
9	Deep Track Capital, Lp	3.62%	3.57M	$26.17M
10	Armistice Capital, LLC	3.25%	3.20M	$23.49M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SLDB

No recent headlines available.

SLDB · Healthcare